{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02323477",
      "OrgStudyIdInfo": {
        "OrgStudyId": "741.STZ.2014"
      },
      "Organization": {
        "OrgFullName": "Ankara University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Human Umbilical Cord Stroma MSC in Myocardial Infarction",
      "OfficialTitle": "The Efficacy and Safety Assessment of Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction; a Phase 1/2 Clinical Trial (HUC-HEART Study)",
      "Acronym": "HUC-HEART"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2020",
      "OverallStatus": "Terminated",
      "WhyStopped": "Due to budget limitations as allocated for a given period.",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2, 2015",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 30, 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 30, 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 18, 2014",
      "StudyFirstSubmitQCDate": "December 18, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 23, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 8, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 10, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Alp Can",
        "ResponsiblePartyInvestigatorTitle": "Prof. Dr.",
        "ResponsiblePartyInvestigatorAffiliation": "Ankara University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Ankara University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Hacettepe University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Turkiye Yuksek Ihtisas Education and Research Hospital",
            "CollaboratorClass": "OTHER_GOV"
          },
          {
            "CollaboratorName": "Atigen-Cell and Tissue Center",
            "CollaboratorClass": "INDUSTRY"
          },
          {
            "CollaboratorName": "Dr. Sami Ulus Children's Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Ankara Yildirim BeyazÄ±t University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this phase 1/2 clinical trial is to evaluate the efficacy and safety of allogeneic human umbilical cordstroma derived multipotent stem cells (hUCS-MSCs) in myocardial infarction (MI). All subjects will be taken into the bypass coronary surgery prior to the cell administration. This 2-year study comprise three independent groups, where the first group (n=20) will take no cells, second group will take autologous BM-MNCs (n=20), and third group (n=39) will be receiving allogeneic hUCS-MSCs. In all transplantations cells will be administered to the approximately 10 peri-infarct areas at one time. The infarct zone will be determined by the MR, SPECT and PET imaging. Only male subjects between 30-80 years of age. The efficiency of the therapy will be evaluated according to the parameters measured by MR, SPECT, and Echocardiography. All subject were taken into those measurements prior and 6, 12, 18 and 24 months after the operation."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Ischemic Cardiomyopathy",
          "Coronary Artery Bypass Surgery"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "cellular therapy",
          "chronic ischemic heart disease",
          "phase 1/2 clinical study",
          "human umbilical cord multipotent stem cell",
          "human umbilical cord mesenchymal stem cell",
          "ischemic heart disease",
          "bone marrow mononuclear cell",
          "allogeneic stem cell transplantation"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "46",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Allogeneic umbilical cord MSC group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: stem cell transplantation"
              ]
            }
          },
          {
            "ArmGroupLabel": "Autologous bone marrow-derived MNC group",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: stem cell transplantation"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control group",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "stem cell transplantation",
            "InterventionDescription": "Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Allogeneic umbilical cord MSC group",
                "Autologous bone marrow-derived MNC group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "ventricular remodeling",
            "PrimaryOutcomeDescription": "Outcome measures will be determined by cardiac MR, SPECT and PET monitoring to assess the left ventricular ejection fraction (%), left ventricle end-diastolic and end-systolic volumes (mL/m2), left ventricle mass (g/m2), infarct size (%), and the thickness of the dysfunctional wall (mm).",
            "PrimaryOutcomeTimeFrame": "within one year after cell transplantation"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nIschemic hearth disease who will experience CABG\n%25<EF<%45\nNYHA class II-IV patients\nhemodynamically stable\n\nExclusion Criteria:\n\nPatient's in approval\nAcute cardiac decompensation\nAcute myocardial infarction\nCongenital heart disease\nAdditional surgical heart disease other than coronary artery disease\nMalign arrhythmia\nAll malignancies\nHbA1c level >%10 (86 mmol/mol) type II diabetes mellitus\nSevere liver dysfunction\nSevere COPD\nCoagulopathy\nImmunosuppressive treatment\nAcute hepatitis, hepatitis B, C and HIV infection\nChronic liver and renal failure\nCollagen tissue disease\nStroke\nTB\nHematological diseases\nSocially and mentally disabilities",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "MinimumAge": "30 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Alp Can",
            "LocationCity": "Ankara",
            "LocationZip": "06100",
            "LocationCountry": "Turkey"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32840230",
            "ReferenceType": "derived",
            "ReferenceCitation": "Ulus AT, Mungan C, Kurtoglu M, Celikkan FT, Akyol M, Sucu M, Toru M, Gul SS, Cinar O, Can A. Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial). Int J Stem Cells. 2020 Nov 30;13(3):364-376. doi: 10.15283/ijsc20075."
          },
          {
            "ReferencePMID": "26123356",
            "ReferenceType": "derived",
            "ReferenceCitation": "Can A, Ulus AT, Cinar O, Topal Celikkan F, Simsek E, Akyol M, Canpolat U, Erturk M, Kara F, Ilhan O. Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting. Stem Cell Rev Rep. 2015 Oct;11(5):752-60. doi: 10.1007/s12015-015-9601-0."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009203",
            "ConditionMeshTerm": "Myocardial Infarction"
          },
          {
            "ConditionMeshId": "D000009202",
            "ConditionMeshTerm": "Cardiomyopathies"
          },
          {
            "ConditionMeshId": "D000007238",
            "ConditionMeshTerm": "Infarction"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007511",
            "ConditionAncestorTerm": "Ischemia"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000009336",
            "ConditionAncestorTerm": "Necrosis"
          },
          {
            "ConditionAncestorId": "D000017202",
            "ConditionAncestorTerm": "Myocardial Ischemia"
          },
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11307",
            "ConditionBrowseLeafName": "Myocardial Infarction",
            "ConditionBrowseLeafAsFound": "Myocardial Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9434",
            "ConditionBrowseLeafName": "Infarction",
            "ConditionBrowseLeafAsFound": "Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5698",
            "ConditionBrowseLeafName": "Coronary Artery Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18658",
            "ConditionBrowseLeafName": "Myocardial Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11306",
            "ConditionBrowseLeafName": "Cardiomyopathies",
            "ConditionBrowseLeafAsFound": "Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11436",
            "ConditionBrowseLeafName": "Necrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}